Lianzhong Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lianzhong Zhang has a total of 148 co-authors. Here are the top co-authors by number of shared publications:
Shaobo Duan
Department of Ultrasound, Henan Provincial International Joint Laboratory of Ultrasonic Nanotechnology and Artificial Intelligence in Precision Theragnostic Systems, Zhengzhou, 450003, People’s Republic of China
25 shared publicationsYaqiong Li
Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, 450003, China
11 shared publicationsLinlin Zhang
Department of Ultrasound, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, 450003, People’s Republic of China
10 shared publicationsShanshan Ren
Department of Ultrasound, Henan Provincial People’s Hospital, Zhengzhou, China
10 shared publicationsXiguo Cai
Henan Provincial Clinical Research Center for Rehabilitation Medicine, Zhengzhou, 450003, People’s Republic of China
10 shared publicationsJuan Zhang
Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China
9 shared publications
Latest Publications
- 7 April 2026
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 265, 115691
Ultrasound-driven nanotechnologies to overcome cancer immunotherapy resistance: From antigen presentation to metabolic rewiring
- 7 April 2026
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 265, 115691
Ultrasound-driven nanotechnologies to overcome cancer immunotherapy resistance: From antigen presentation to metabolic rewiring
- Open Access
- 1 April 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-22
An Active-Targeted ZIF8-Based Nanotheranostic Platform for Ultrasound Imaging-Guided Synergistic Therapy of Triple-Negative Breast Cancer
Purpose: To address the therapeutic challenges associated with triple-negative breast cancer (TNBC), we developed a folic acid-polyethylene glycol-modified ZIF8-based nanotheranostic platform (FA-PEG@ZIF8@CIP) designed to integrate synergistic sonodynamic therapy, chemotherapy, and immune activation for enhanced antitumor treatment. Methods: FA-PEG@ZIF8@CIP was constructed as a folic acid-polyethylene glycol-functionalized ZIF8 nanoplatform for the delivery of ciprofloxacin. In this system, ciprofloxacin acted as both a sonosensitizer and a chemotherapeutic agent, while the ZIF8 carrier provided pH-responsive release behavior in the acidic tumor microenvironment. The platform was further evaluated for its physicochemical properties, cellular uptake, antitumor efficacy, immune activation, and ultrasound imaging performance through a series of in vitro and in vivo experiments. Results: FA-PEG@ZIF8@CIP exhibited favorable tumor-targeting capability and potent antitumor activity. Under ultrasound irradiation, the platform markedly enhanced reactive oxygen species (ROS) generation, leading to effective tumor cell killing. In addition, it induced immunogenic cell death (ICD), as evidenced by enhanced calreticulin exposure, HMGB1 translocation, and extracellular ATP release. These effects further promoted dendritic cell maturation and increased cytotoxic T-lymphocyte infiltration within tumor tissues, indicating activation of antitumor immune responses. The proportions of CD8+ T cells in tumor tissues and spleen increased to 18.7% and 14.6%, respectively, corresponding to approximately 3.0-fold and 2.9-fold increases over the PBS group. The antitumor efficacy of FA-PEG@ZIF8@CIP+US was 4.21-fold higher than that of PBS. Moreover, the platform demonstrated effective ultrasound imaging capability, supporting its application for imaging-guided therapy. Collectively, these findings suggest that FA-PEG@ZIF8@CIP exerts therapeutic effects through the coordinated actions of sonodynamic therapy, chemotherapy, and immune modulation. Conclusion: This multifunctional nanosystem enables the integration of diagnosis and therapy and represents a promising strategy for TNBC treatment. By combining targeted delivery, pH-responsive drug release, ultrasound imaging, and synergistic therapeutic effects within a single platform, FA-PEG@ZIF8@CIP may offer a valuable approach for improving theranostic outcomes in TNBC.
- 1 April 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-22
Open AccessAn Active-Targeted ZIF8-Based Nanotheranostic Platform for Ultrasound Imaging-Guided Synergistic Therapy of Triple-Negative Breast Cancer
Purpose: To address the therapeutic challenges associated with triple-negative breast cancer (TNBC), we developed a folic acid-polyethylene glycol-modified ZIF8-based nanotheranostic platform (FA-PEG@ZIF8@CIP) designed to integrate synergistic sonodynamic therapy, chemotherapy, and immune activation for enhanced antitumor treatment. Methods: FA-PEG@ZIF8@CIP was constructed as a folic acid-polyethylene glycol-functionalized ZIF8 nanoplatform for the delivery of ciprofloxacin. In this system, ciprofloxacin acted as both a sonosensitizer and a chemotherapeutic agent, while the ZIF8 carrier provided pH-responsive release behavior in the acidic tumor microenvironment. The platform was further evaluated for its physicochemical properties, cellular uptake, antitumor efficacy, immune activation, and ultrasound imaging performance through a series of in vitro and in vivo experiments. Results: FA-PEG@ZIF8@CIP exhibited favorable tumor-targeting capability and potent antitumor activity. Under ultrasound irradiation, the platform markedly enhanced reactive oxygen species (ROS) generation, leading to effective tumor cell killing. In addition, it induced immunogenic cell death (ICD), as evidenced by enhanced calreticulin exposure, HMGB1 translocation, and extracellular ATP release. These effects further promoted dendritic cell maturation and increased cytotoxic T-lymphocyte infiltration within tumor tissues, indicating activation of antitumor immune responses. The proportions of CD8+ T cells in tumor tissues and spleen increased to 18.7% and 14.6%, respectively, corresponding to approximately 3.0-fold and 2.9-fold increases over the PBS group. The antitumor efficacy of FA-PEG@ZIF8@CIP+US was 4.21-fold higher than that of PBS. Moreover, the platform demonstrated effective ultrasound imaging capability, supporting its application for imaging-guided therapy. Collectively, these findings suggest that FA-PEG@ZIF8@CIP exerts therapeutic effects through the coordinated actions of sonodynamic therapy, chemotherapy, and immune modulation. Conclusion: This multifunctional nanosystem enables the integration of diagnosis and therapy and represents a promising strategy for TNBC treatment. By combining targeted delivery, pH-responsive drug release, ultrasound imaging, and synergistic therapeutic effects within a single platform, FA-PEG@ZIF8@CIP may offer a valuable approach for improving theranostic outcomes in TNBC.
- Open Access
- 5 February 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Biosynthetic OMVs with endogenous GM-CSF loading for ultrasound-triggered in situ cancer vaccination
Impaired dendritic cell (DC) recruitment, maturation, and antigen presentation within the immunosuppressive tumor microenvironment (TME) critically limit t
- 5 February 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessBiosynthetic OMVs with endogenous GM-CSF loading for ultrasound-triggered in situ cancer vaccination
Impaired dendritic cell (DC) recruitment, maturation, and antigen presentation within the immunosuppressive tumor microenvironment (TME) critically limit t
- 11 September 2025
- Published by Elsevier in Biomaterials
- Vol. 326, 123695
Nanoengineered T cell membrane-coated nanodecoys blocking LAG-3/FGL1 to enhance cancer immunotherapy
- 11 September 2025
- Published by Elsevier in Biomaterials
- Vol. 326, 123695
Nanoengineered T cell membrane-coated nanodecoys blocking LAG-3/FGL1 to enhance cancer immunotherapy
- Open Access
- 4 July 2025
- Published by Elsevier in Materials Today Bio
- Vol. 33, 102043
Sonogenetics regulation of intelligent engineered bacteria to reverse immune escape
- 4 July 2025
- Published by Elsevier in Materials Today Bio
- Vol. 33, 102043
Open AccessSonogenetics regulation of intelligent engineered bacteria to reverse immune escape
- 27 June 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 385, 113988
Ultrasound-activated nanovesicles for adenosine exhaustion and immune checkpoint blockade in cancer immunotherapy
- 27 June 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 385, 113988
Ultrasound-activated nanovesicles for adenosine exhaustion and immune checkpoint blockade in cancer immunotherapy
- Open Access
- 28 April 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1565618
Machine learning-based ultrasound radiomics for predicting TP53 mutation status in hepatocellular carcinoma
Objectives: To explore the utility of machine learning-based ultrasound radiomics for predicting TP53 gene mutation in hepatocellular carcinoma (HCC).Methods: 154 HCC patients with 182 lesions from 2019 to 2024 were reviewed retrospectively. All lesions were randomly split into the training set (n = 129) and the test set (n = 53), and ultrasound radiomics features were extracted and selected. Extreme gradient boosting tree (XGBoost), decision tree (DT), random forest (RF), support vector machine (SVM), and logistic regression (LR) were used to construct the ultrasound radiomics models, the clinical models, and the combined models. The predictive performance of various models was evaluated by the area under the curve (AUC), accuracy, calibration curve, and decision curve analysis (DCA).Results: Among the 182 lesions, 102 were confirmed as mutant TP53 and 80 were confirmed as wild-type TP53. The ultrasound radiomics model obtained an AUC of 0.778 and an accuracy of 0.774 in the test set. The clinical model achieved an AUC of 0.761 and an accuracy of 0.710 in the test set. Notably, integrating clinical features with ultrasound radiomics further enhanced predictive performance. The XGBoost-based combined model exhibited the highest predictive performance among all models, achieving an AUC of 0.846 and an accuracy of 0.823 in the test set. The decision curve analysis and calibration curve revealed that the XGBoost-based combined model provided the highest clinical benefit and exhibited strong predictive consistency.Conclusion: Machine learning-based ultrasound radiomics signatures accurately predict TP53 gene mutations in HCC. The XGBoost-based combined model, which combined ultrasound radiomics features with clinical features, showed the best performance and represented a promising noninvasive approach for screening TP53-mutated HCC.
- 28 April 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1565618
Open AccessMachine learning-based ultrasound radiomics for predicting TP53 mutation status in hepatocellular carcinoma
Objectives: To explore the utility of machine learning-based ultrasound radiomics for predicting TP53 gene mutation in hepatocellular carcinoma (HCC).Methods: 154 HCC patients with 182 lesions from 2019 to 2024 were reviewed retrospectively. All lesions were randomly split into the training set (n = 129) and the test set (n = 53), and ultrasound radiomics features were extracted and selected. Extreme gradient boosting tree (XGBoost), decision tree (DT), random forest (RF), support vector machine (SVM), and logistic regression (LR) were used to construct the ultrasound radiomics models, the clinical models, and the combined models. The predictive performance of various models was evaluated by the area under the curve (AUC), accuracy, calibration curve, and decision curve analysis (DCA).Results: Among the 182 lesions, 102 were confirmed as mutant TP53 and 80 were confirmed as wild-type TP53. The ultrasound radiomics model obtained an AUC of 0.778 and an accuracy of 0.774 in the test set. The clinical model achieved an AUC of 0.761 and an accuracy of 0.710 in the test set. Notably, integrating clinical features with ultrasound radiomics further enhanced predictive performance. The XGBoost-based combined model exhibited the highest predictive performance among all models, achieving an AUC of 0.846 and an accuracy of 0.823 in the test set. The decision curve analysis and calibration curve revealed that the XGBoost-based combined model provided the highest clinical benefit and exhibited strong predictive consistency.Conclusion: Machine learning-based ultrasound radiomics signatures accurately predict TP53 gene mutations in HCC. The XGBoost-based combined model, which combined ultrasound radiomics features with clinical features, showed the best performance and represented a promising noninvasive approach for screening TP53-mutated HCC.
- Open Access
- 3 April 2025
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 8 (15) , 7825-7839
Graphene Oxide Modified Microbubble for the Ultrasonic Imaging and Treatment of Hepatocellular Carcinoma
- 3 April 2025
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 8 (15) , 7825-7839
Open AccessGraphene Oxide Modified Microbubble for the Ultrasonic Imaging and Treatment of Hepatocellular Carcinoma
- Open Access
- 1 April 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 715-727
Preoperative Prediction of Macrotrabecular-Massive Hepatocellular Carcinoma Using Machine Learning-Based Ultrasomics
Purpose: Macrotrabecular-massive hepatocellular carcinoma (MTM-HCC) is a special pathological subtype of HCC, which is related to invasiveness and poor prognosis. We aimed to construct an ultrasomics model for preoperative noninvasive prediction of MTM-HCC. Patients and Methods: Patients with pathologically confirmed HCC who underwent liver surgery between January 2021 and December 2023 were retrospectively enrolled. 211 eligible patients (169 males and 42 females) were divided 7:3 into the training set (n=147) and test set (n=64) by random stratified sampling. Ultrasomics models were constructed based on the ultrasound image features of the training set using five different ML algorithms, including random forest (RF), eXtreme gradient boosting (XGBoost), support vector machine (SVM), decision tree (DT), and logistic regression (LR). Additionally, a model based on clinical features and a combined model based on clinical and ultrasomics features were constructed to predict MTM-HCC. The performance of the models in the preoperative prediction of MTM-HCC was evaluated on the test set using area under the receiver operating characteristic curve (AUC), sensitivity, specificity, and accuracy. Results: The ultrasomics models and the combined models of the five algorithms were effective in predicting MTM-HCC, and the combined models have improved AUC after adding clinical features compared with the ultrasomics model in the test set. The model constructed based on the RF algorithm in the test set has a high accuracy rate and specificity, and the overall performance of the models is better than that of the other four algorithm models, the AUC, accuracy, specificity, and sensitivity of its combined model and ultrasomics model are significantly higher than the clinical model. Conclusion: ML-based ultrasomics model is an effective tool for predicting MTM-HCC before surgery. Integrating clinical and ultrasound image features enhances predictive performance, offering a novel approach for non-invasive preoperative diagnosis of MTM-HCC.
- 1 April 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 715-727
Open AccessPreoperative Prediction of Macrotrabecular-Massive Hepatocellular Carcinoma Using Machine Learning-Based Ultrasomics
Purpose: Macrotrabecular-massive hepatocellular carcinoma (MTM-HCC) is a special pathological subtype of HCC, which is related to invasiveness and poor prognosis. We aimed to construct an ultrasomics model for preoperative noninvasive prediction of MTM-HCC. Patients and Methods: Patients with pathologically confirmed HCC who underwent liver surgery between January 2021 and December 2023 were retrospectively enrolled. 211 eligible patients (169 males and 42 females) were divided 7:3 into the training set (n=147) and test set (n=64) by random stratified sampling. Ultrasomics models were constructed based on the ultrasound image features of the training set using five different ML algorithms, including random forest (RF), eXtreme gradient boosting (XGBoost), support vector machine (SVM), decision tree (DT), and logistic regression (LR). Additionally, a model based on clinical features and a combined model based on clinical and ultrasomics features were constructed to predict MTM-HCC. The performance of the models in the preoperative prediction of MTM-HCC was evaluated on the test set using area under the receiver operating characteristic curve (AUC), sensitivity, specificity, and accuracy. Results: The ultrasomics models and the combined models of the five algorithms were effective in predicting MTM-HCC, and the combined models have improved AUC after adding clinical features compared with the ultrasomics model in the test set. The model constructed based on the RF algorithm in the test set has a high accuracy rate and specificity, and the overall performance of the models is better than that of the other four algorithm models, the AUC, accuracy, specificity, and sensitivity of its combined model and ultrasomics model are significantly higher than the clinical model. Conclusion: ML-based ultrasomics model is an effective tool for predicting MTM-HCC before surgery. Integrating clinical and ultrasound image features enhances predictive performance, offering a novel approach for non-invasive preoperative diagnosis of MTM-HCC.
- Open Access
- 24 March 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1527763
Ultrasound-guided percutaneous radiofrequency ablation combined with anti-PD-1 for the treatment of prostate cancer: an experimental study
Background: This study seeks to investigate the potential synergistic effects of combining ultrasound-guided percutaneous radiofrequency ablation with anti-PD-1 therapy on prostate cancer, utilizing animal models.Methods: A mouse model of prostate cancer was established by subcutaneous injection of 1 × 106 Myc-Cap cells on the right side of FVB mice. When the volume of the tumors reached about 400mm3, the mice were randomly divided into four groups and received corresponding intervention treatments. Among them, Group 1 was the blank control group, Group 2 was the simple anti-PD-1 treatment group, Group 3 was the simple radiofrequency ablation group, and Group 4 is the group that received percutaneous radiofrequency ablation combined with anti-PD-1 therapy under ultrasound guidance. The growth of the tumors was observed in mice after treatment in each group, tumor tissues were collected, and the immune status of the mice was analyzed through flow cytometry, immunohistochemistry, immunofluorescence, and other methods.Results: Compared with other treatment groups, ultrasound-guided percutaneous radiofrequency ablation combined with anti-PD-1 therapy significantly reduced the weight and volume of the tumors, demonstrating more effective tumor suppression. At the same time, combination therapy can promote the aggregation of T-cells within the tumor and increase the proportion of cytotoxic T-cells, increase the proportion of M1 macrophages and iNOS expression, and decrease the proportion of M2 macrophages and Arg expression in the local area of the tumors.Conclusion: Local ablation can improve the therapeutic effect of PD-1 monoclonal antibody. Our preliminary results suggest that ultrasound-guided percutaneous radiofrequency ablation, in combination with anti-PD-1 treatment, produces synergistic effects. These effects may be driven by changes in immune cell populations within the tumor’s immunosuppressive microenvironment.
- 24 March 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1527763
Open AccessUltrasound-guided percutaneous radiofrequency ablation combined with anti-PD-1 for the treatment of prostate cancer: an experimental study
Background: This study seeks to investigate the potential synergistic effects of combining ultrasound-guided percutaneous radiofrequency ablation with anti-PD-1 therapy on prostate cancer, utilizing animal models.Methods: A mouse model of prostate cancer was established by subcutaneous injection of 1 × 106 Myc-Cap cells on the right side of FVB mice. When the volume of the tumors reached about 400mm3, the mice were randomly divided into four groups and received corresponding intervention treatments. Among them, Group 1 was the blank control group, Group 2 was the simple anti-PD-1 treatment group, Group 3 was the simple radiofrequency ablation group, and Group 4 is the group that received percutaneous radiofrequency ablation combined with anti-PD-1 therapy under ultrasound guidance. The growth of the tumors was observed in mice after treatment in each group, tumor tissues were collected, and the immune status of the mice was analyzed through flow cytometry, immunohistochemistry, immunofluorescence, and other methods.Results: Compared with other treatment groups, ultrasound-guided percutaneous radiofrequency ablation combined with anti-PD-1 therapy significantly reduced the weight and volume of the tumors, demonstrating more effective tumor suppression. At the same time, combination therapy can promote the aggregation of T-cells within the tumor and increase the proportion of cytotoxic T-cells, increase the proportion of M1 macrophages and iNOS expression, and decrease the proportion of M2 macrophages and Arg expression in the local area of the tumors.Conclusion: Local ablation can improve the therapeutic effect of PD-1 monoclonal antibody. Our preliminary results suggest that ultrasound-guided percutaneous radiofrequency ablation, in combination with anti-PD-1 treatment, produces synergistic effects. These effects may be driven by changes in immune cell populations within the tumor’s immunosuppressive microenvironment.